Like an approved U.S. patent app...for example shown here earlier..it looked real when posted but no PR yet for some reason.
News between now and next p2 release will likely move +/- SP. IMO, the longer this goes w/o legitimate negative news then even minor positve will have big impact. The bias is highly positive. What price can be put on the quality of life for people who have paid their dues? I like the fact that patients may well be able to validate clinical diagnostics and metrics. Now that may never happen but, itf it does, the claim of breakthrough is virtually certain. Priceless.
Patent application 14/205637 was issued a NOTICE OF ALLOWANCE on 7/27/15, meaning it has been "examined and is allowed for issuance as a patent."
This is the patent application that covers Anavex 2-73 in combination with other compounds for the treatment of cancer and neuropathic pain. PR was issued earlier this year regarding the beneficial interaction between sigma-1 and cannabinoid receptors, which is relevant to this patent application due to the cannabinoid receptor's involvement in the regulation of neuropathic pain. From the PR:
“With Anavex drug candidates targeting the sigma-1 receptor, and with the mechanism of action being further validated, we are even more encouraged to advance our studies with additional neurodegenerative diseases,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The Company is intrigued to realize the direct link to the body’s endocannabinoid system and to proceed with potential studies with our sigma-1 drugs candidates and cannabinoids.”
While this patent application is unrelated to Anavex PLUS, this is great news because it represents the first U.S. patent to be issued for Anavex 2-73. Application 13/940352 (Anavex PLUS) is still waiting to be picked up for examination, so any update there is likely still months away. For now, let's celebrate this first victory on the IP front. Less
I agree. The trial has very tight rules. How much discretionary authority is there to act when cases like this present themselves? For example, this soldier may be outside the age window.
Pros, do you know of any interim (between now and the end of Sept.) conferences or media events which might be used to relay new AVXL information? AVXL has other indications. Surely, considering your post, interest and pressure will build for new/more information. Any planned events which might help to mitigate a boom-bust scenario?
wild...all the best. Your comment below presents the fundamental logic that has me positive on AVXL. Unless the results recently presented in DC are a complete fabrication(unlikely given the conference/DD and peer review). Although we are only just beginning to see this treatments efficacy, nothing even close to these results have ever been published. And, although a false positve comment from patients and caregivers is possible, who better than the pateint to describe results? All other AD trials can only measure efficacy by autopsy, Which seems almost midevil by contrast. Cannot wait until next results are available, hope we have some kind of interim publication.
"An advantage of A2-73 is that the P300 test that showed a 400% improvement over donepezil, which is the official "Standard of Care" for Alzheimer's. Donepezil was proven long ago to be better than placebo, so if A2-73 is better than donepezil, it has to be better than placebo... *if* the p2a interim report results are confirmed in the full p2a and subsequent p2 results."
Timing of buyout could surprise us all. The big P have been dumping billions into AD for years. If there is a hint of P2 repeat results(even though (n ) is small)they have to act fast or lose the whole game. Massive spend and time has produced ZERO up till now. If this is real then caution will not be on the agenda. BP Effort will be huge and immediate, IMO.